Insulet Corporation

Insulet Corporation is an innovative medical device company headquartered in Acton, Massachusetts, dedicated to transforming the lives of people with diabetes. Its core mission is to improve the lives of individuals with diabetes by providing simplicity, freedom, and healthier outcomes through advanced, user-friendly technology, aiming for a world where diabetes demands less every day.

The company's flagship offering is the Omnipod Insulin Management System, which includes the Omnipod 5 Automated Insulin Delivery System and Omnipod DASH. This system features tubeless, wearable, disposable Pods that deliver continuous insulin for up to three days, eliminating the need for traditional injections. The Omnipod 5 integrates with continuous glucose monitoring systems to automate insulin delivery, serving individuals with both Type 1 and an expanding segment of Type 2 diabetes, and its technology is also being explored for other subcutaneous drug delivery applications. Insulet's products are available in 25 countries globally.

Insulet maintains a strong market position as a global leader in tubeless insulin pump technology, with the Omnipod 5 being the most prescribed automated insulin delivery system in the U.S. in 2024. The company reported over $2.1 billion in revenue for 2024, demonstrating consistent growth. Recent developments include a voluntary medical device correction for certain Omnipod 5 Pod lots in April 2026, alongside continued global expansion into new markets in the Middle East and planned entry into Spain by late 2026. Ashley McEvoy is identified as the CEO.